Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and...

Area of Science:

• Neuroscience and Psychiatry
• Psychopharmacology
• Clinical Research Methodologies

Background:

• Psilocybin is a promising psychedelic compound for treating various neuropsychiatric disorders.
• Conventional randomized controlled trials (RCTs) may not fully capture psilocybin's therapeutic complexity, which involves pharmacological, contextual, and psychological factors.
• Existing research frameworks need evaluation for assessing psilocybin's therapeutic potential.

Purpose of the Study:

• To critically review the adequacy of current clinical research frameworks for psilocybin.
• To explore alternative methodologies that better reflect real-world clinical conditions.
• To synthesize clinical outcomes, methodological constraints, and epistemic considerations of psychedelic-assisted therapy.

Main Methods:

• Analysis of the ten most cited clinical studies on psilocybin (2015-2025) from Web of Science.
• Inclusion of additional literature via cross-checking, systematic reviews, meta-analyses, and interdisciplinary sources.
• Synthesis of clinical outcomes, methodological limitations, and real-world evidence (RWE).

Main Results:

• Highly cited trials show rapid, sustained antidepressant and anxiolytic effects of psilocybin.
• Methodological limitations include selection bias, blinding challenges, small sample sizes, and underrepresentation of diverse populations.
• Psilocybin outcomes are influenced by subjective experience and context; RWE offers insights beyond RCTs.

Conclusions:

• Psilocybin demonstrates significant therapeutic potential, but current RCTs capture only a partial view of its effects.
• Comprehensive evaluation requires larger, diverse trials, long-term follow-up, standardized protocols, and integration of RWE.
• Psychedelic-assisted therapy is a complex intervention combining pharmacological and psychotherapeutic elements.